Distribution, Elimination, and Renal Handling of (99m)Technetium-Demogastrin 1
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F12%3A10123990" target="_blank" >RIV/00216208:11160/12:10123990 - isvavai.cz</a>
Result on the web
<a href="http://online.liebertpub.com/doi/abs/10.1089/cbr.2011.1008" target="_blank" >http://online.liebertpub.com/doi/abs/10.1089/cbr.2011.1008</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1089/cbr.2011.1008" target="_blank" >10.1089/cbr.2011.1008</a>
Alternative languages
Result language
angličtina
Original language name
Distribution, Elimination, and Renal Handling of (99m)Technetium-Demogastrin 1
Original language description
Radiolabeled cholecystokinin/gastrin (CCK) receptor-targeting peptides are promising compounds for radio-diagnosis and radiotherapy of certain malignancies. This study evaluated the pharmacokinetic profile of a CCK-2 receptor-specific peptide, Demogastrin 1, labeled with technetium-99m (Tc-99m-Demogastrin 1), in rats. To investigate the fate of Tc-99m-Demogastrin 1 in the rat, biodistribution and elimination studies in vivo were performed, and elimination parameters in perfused rat liver and kidney weredetermined. Biodistribution studies showed that Tc-99m-Demogastrin 1 was rapidly cleared from the blood and most organs. A significant amount of radioactivity was detected in the CCK-2 receptor-rich organs, such as the stomach. Low radioactivity was found in the CCK-1 receptor-rich organs. Radioactivity in bowels and stomach declined relatively slowly. High and long-term retention of radioactivity in the kidneys was observed. Elimination of Tc-99m-Demogastrin 1 via the bile was negligib
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Biotherapy and Radiopharmaceuticals
ISSN
1084-9785
e-ISSN
—
Volume of the periodical
27
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
169-174
UT code for WoS article
000301440900010
EID of the result in the Scopus database
—